Dermatological procedures performed purely under local anaesthesia can provide excellent intraoperative analgesia. However, post-procedure patients can have significant pain. Consequences of pain include patient distress, poor compliance with dressings and subsequent delayed wound healing as well as the potential fear and avoidance of further procedures. Anecdotally the same postoperative analgesia regime is given to all dermatology patients. There is a general fear by dermatologists of nonsteroidal anti-inflammatory drugs (NSAIDs) due to perceived risk of postoperative bleeding and of tramadol due to its sedative effects. Understanding of pharmacology within the patient population and their comorbidities is necessary in choosing the appropriate analgesic regime. We reviewed the most commonly used analgesics, giving a summary of the important pharmacology and evidence of their use in the literature in order to allow clinicians to give individual approach to managing post-procedure analgesia.
INTRODUCTION
Dermatological procedures vary in the magnitude of pain they produce. Photodynamic therapy is considered extremely painful by most patients, 1,2 whereas Mohs micrographic surgery is generally well tolerated with little to no pain reported after 1 week. 3 When planning a patient's analgesia, one must consider patient, procedure and social factors. Patient factors include age, allergy status, comorbidities, concurrent medication and any changes in physiology, such as pregnancy and breast feeding. Procedural factors include the site and magnitude of procedure and the anticipated duration of pain afterwards. Social factors can be very relevant such as whether the patient needs to be able to drive home or work the next day, or whether drowsiness or confusion can be tolerated.
PHYSIOLOGY OF PAIN
Pain can be either nociceptive or neuropathic. Nociceptive pain is caused by stimulation of nociceptors. Neuropathic pain is due to damage or dysfunction of the nervous system. Pain following dermatological procedures is predominantly nociceptive. Nociceptors in the skin are free nerve endings of primary sensory neurones stimulated either directly by surgical trauma or sensitised by mediators of inflammation. Sharp and well-localised pain is transmitted by fast myelinated A-delta fibres. Slower un-myelinated C-fibres transmit duller less well localised pain. The pain impulse ascends first via secondary afferent nerves within the spinothalamic tracts to the thalamus, followed by tertiary afferent neurones ascending to the somatosensory cortex. Numerous additional ascending and descending pathways also exist, which can modulate the pain signal. 
COMMONLY USED ANALGESICS

NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS)
NSAIDs act by inhibiting the cyclooxygenase (COX) enzymes resulting in decreased quantities of prostenoids.
Supplementary figure 1 shows some of the roles of the prostenoids which helps to explain NSAIDs side effects. NSAIDs can be classified broadly into two: nonselective, such as ibuprofen and diclofenac which inhibit all COX enzymes and selective COX2 inhibitors (also known as 'coxibs') such as celecoxib. COX1 is a constitutive enzyme produced by cells under normal physiological conditions. COX2 is an inducible enzyme produced during inflammation. By only inhibiting, the COX2 enzyme the selective NSAIDs demonstrate a more favourable side effect profile. 4 Intramuscular paracoxib provides effective, safe and long acting analgesia, a particularly useful method of pain control in the first 24 h following a procedure. 5 There are well recognised gastrointestinal, renal and cardiovascular safety concerns with all NSAIDs. 6 Complications from NSAID are influenced by type of NSAID, dose, duration of treatment, patient comorbidities and concurrent medication. A meta-analysis of 754 trials found COX2 inhibitors increased the risk of major vascular events by about a third. 7 This increased risk was also associated with high dose diclofenac (150 mg/day) and possibly with high dose ibuprofen (2400 mg/day). Naproxen did not significantly increase major vascular events. The meta-analysis found that all NSAIDs increase the risk of heart failure and upper gastrointestinal complications. What is not known is the risk of low dose short-term exposure to these medicines which would be the normal setting following a dermatological procedure. NSAIDs increase bleeding time by inhibition of the COX1 enzyme resulting in decreased thromboxane A2; a potent vasoconstrictor and essential element of platelet aggregation. Aspirin inhibits the enzyme irreversibly for the lifetime of the platelet, approximately 7-14 days. Other NSAIDs are reversible, and hence, the effects are shorter and dependant on dose, distribution, half-life and clearance. Anecdotally, NSAIDs are often avoided following dermatological surgery for fear of postoperative bleeding. A meta-analysis of 36 randomised control trials with over 3000 patients found no increased bleeding following the use of NSAIDs in the adult or paediatric post tonsillectomy population concluding NSAIDs are a safe method of analgesia. 8 A systematic review regarding the use of ibuprofen for 7 days postoperatively in plastic surgery including Mohs defect reconstruction found no increased risk of postoperative bleeding or haematoma. 9 A large prospective randomised multicentre trial evaluating the safety of ketorolac versus diclofenac or ketoprofen for pain control after major surgery found all to be equally safe. 10 The trial included 3256 patients undergoing plastic/ENT surgery. A significant increased risk of postoperative bleeding in patients given postoperative anticoagulation for thromboprophylaxis was noted. Despite the absolute risk of bleeding being small, there remains insufficient evidence regarding the safe use of NSAIDs postoperatively in patients established on an anticoagulant preoperatively.
NSAIDs pose some key advantages to other analgesics; they are anti-inflammatory, anti-pyrexial as well as analgesic. Unlike opioids, they do not induce any respiratory compromise, confusion, constipation or dependence. Table 1 shows the contraindications to NSAID use. In patients with end-stage renal failure or severe heart failure, these drugs must be avoided. However, there is a large grey area of patients with mild-to-moderate disease who may benefit from the opioid sparing analgesia NSAIDs offer. A risk benefit approach must be taken when considering NSAIDs using the lowest dose for the least length of time. Avoidance for fear of a complication is not justified in the main.
OPIOIDS
Opioids encompass naturally occurring opiates (morphine and codeine) and synthetic drugs which act on the opioids receptors (dihydrocodeine and oxycodone). Opioids are a large family of drugs with differing pharmacokinetic and pharmacodynamic profiles resulting in a range of therapeutic and unwanted effects. Table 2 depicts potency variations between opioids. Tramadol is not a pure opioid but some of its actions are at opioid receptors; hence, it is included for comparison.
Morphine
About 10% of morphine is metabolised to morphine-6-glucuronide (M6G), which is 10-20 times more potent than morphine. M6G relies upon renal excretion hence accumulates in renal insufficiency leading to unwanted side effects and toxicity.
Codeine
Codeine must be metabolised to morphine before its clinical effects can be seen. About 5-10% of codeine is metabolised to morphine by the cytochrome P450 system. Genetic variation in cytochrome P450 genes results in varying enzyme activity. Ultra-rapid metabolisers will convert a much higher proportion of codeine to morphine increasing the risk of opioid toxicity. Poor metabolisers are unable to convert codeine to morphine and experience minimal analgesia. 11 Unpredictable metabolism must be considered especially in patients at risk of opioid toxicity.
TRAMADOL
Tramadol has multiple modes of analgesic action. Although one of its mechanisms of action is via the opioid receptors, it has key advantages over the true opioids in that it causes minimal respiratory depression and reduced cardiovascular and gastrointestinal side effects. It is therefore a useful adjuvant for moderate-to-severe pain, particularly in patients who do not tolerate opioids.
CONCLUSION
A sound knowledge of the pharmacologic properties of the commonly prescribed oral analgesics is essential for Dermatologists prescribing analgesia after dermatological procedures. Table 3 is the authors proposed use of analgesia in relation to pain severity. This is especially important in an era of ever increasing complex comorbidities and poly pharmacy. The commonly held belief that NSAIDs should be avoided postoperatively due to risk of bleeding is not supported by recent publications and should not dissuade Dermatologists from prescribing this useful class of analgesics. The importance of forward planning and anticipating pain is essential to improve patient care.
Supporting Information
Additional Supporting Information may be found online in Supporting Information: Figure S1 . Overview of prostenoid production and effects of NSAIDs via COX inhibition. 
